Intellipharmaceutics International Inc
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, car… Read more
Market Cap & Net Worth: Intellipharmaceutics International Inc (IPCIF)
Intellipharmaceutics International Inc (OTCQB:IPCIF) has a market capitalization of $4.96 Million ($4.96 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #31355 globally and #10314 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intellipharmaceutics International Inc's stock price $0.15 by its total outstanding shares 33092700 (33.09 Million).
Intellipharmaceutics International Inc Market Cap History: 2015 to 2024
Intellipharmaceutics International Inc's market capitalization history from 2015 to 2024. Data shows change from $668.47 Million to $4.96 Million (-41.02% CAGR).
Intellipharmaceutics International Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intellipharmaceutics International Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
35.34x
Intellipharmaceutics International Inc's market cap is 35.34 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $668.47 Million | $4.09 Million | -$7.44 Million | 163.29x | N/A |
| 2016 | $939.83 Million | $2.25 Million | -$10.14 Million | 418.26x | N/A |
| 2017 | $264.74 Million | $5.50 Million | -$8.86 Million | 48.10x | N/A |
| 2018 | $8.01 Million | $1.71 Million | -$13.75 Million | 4.67x | N/A |
| 2019 | $27.30 Million | $3.48 Million | -$8.08 Million | 7.84x | N/A |
| 2020 | $4.64 Million | $1.40 Million | -$3.39 Million | 3.31x | N/A |
| 2022 | $2.32 Million | $65.73K | -$2.89 Million | 35.34x | N/A |
Competitor Companies of IPCIF by Market Capitalization
Companies near Intellipharmaceutics International Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Intellipharmaceutics International Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Intellipharmaceutics International Inc Historical Marketcap From 2015 to 2024
Between 2015 and today, Intellipharmaceutics International Inc's market cap moved from $668.47 Million to $ 4.96 Million, with a yearly change of -41.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $4.96 Million | +133.64% |
| 2023 | $2.12 Million | -8.55% |
| 2022 | $2.32 Million | -44.06% |
| 2021 | $4.15 Million | -10.49% |
| 2020 | $4.64 Million | -83.01% |
| 2019 | $27.30 Million | +241.05% |
| 2018 | $8.01 Million | -96.98% |
| 2017 | $264.74 Million | -71.83% |
| 2016 | $939.83 Million | +40.59% |
| 2015 | $668.47 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of Intellipharmaceutics International Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.96 Million USD |
| MoneyControl | $4.96 Million USD |
| MarketWatch | $4.96 Million USD |
| marketcap.company | $4.96 Million USD |
| Reuters | $4.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.